IFNAR1 and neoplasm: The authors further demonstrate that the improved response was due to reduced type I IFN-mediated induction of a granzyme inhibitor, Serpinb9 [104], thus making IFNAR1-deficient tumor cells more sensitive to CD8+ T cell killing.